Arkolith/Insider Trading/ELYM/Form 4

RA Capital Nexus Fund II, L.P.

Director, 10% OwnerEliem Therapeutics, Inc. (ELYM) · full profile →Form 4 · filed Aug 16, 2021
Net Buying
Open-Market Buys
$40.0M
Open-Market Sells
$0
Net Open-Market Flow
$40.0M
Transactions
14
6 non-derivative · 8 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 12, 2021Buy(P)3.0M$12.50$37.6M10.6M
Aug 12, 2021Conversion(C)1.2M——1.2M
Aug 12, 2021Buy(P)195K$12.50$2.4M484K
Aug 12, 2021Conversion(C)625K——841K
Aug 12, 2021Conversion(C)4.7M——7.6M
Aug 12, 2021Conversion(C)288K——288K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 12, 2021Conversion(C)518K—$00
Aug 12, 2021Conversion(C)288K—$00
Aug 12, 2021Conversion(C)485K—$00
Aug 12, 2021Conversion(C)139K—$00
Aug 12, 2021Conversion(C)2.6M—$00
Aug 12, 2021Conversion(C)1.4M—$00
Aug 12, 2021Conversion(C)673K—$00
Aug 12, 2021Conversion(C)708K—$00

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-21-106405) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML